Loading summary
Transcript1 lines
- [00:00]
A
Welcome to Pharma Daily's Week in Review for October 17, 2025. This week, from October 14 to October 17, we covered four major developments in the pharmaceutical and biotech industries. Let's take a look back at the most important stories that shaped our industry this week. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of fascinating updates that underscore a period of significant scientific advancement, strategic partnership partnerships and regulatory developments in the industry, starting with Dianthus Therapeutics, which has taken a bold step by investing up to $1 billion to license a bifunctional fusion protein from Nanjing leads Biolabs. This protein targets autoimmune disorders, a field of immense interest due to the unmet medical needs and potential for breakthrough treatments. Such substantial financial commitments highlight the ongoing trend in the biotech sector towards innovative therapies for autoimmune diseases. In parallel, Sanofi has secured a $500 million agreement with Evoc Therapeutics, continuing its strategic focus on next generation autoimmune technologies. This partnership aligns with Sanofi's broader strategy to leverage cutting edge science in managing autoimmune conditions more effectively. Sanofi's engagement with EVOC Therapeutics stands out as a significant step forward in conquering autoimmune diseases through nanodisk technology designed to facilitate the development of curative treatments for disorders like celiac disease and type 1 diabetes. This collaboration reflects a growing trend among pharmaceutical giants investing in advanced biotechnologies that promise transformative impacts on disease management and patient care. Meanwhile, AstraZeneca's renewed collaboration with Immuni, valued at $85 million, seeks to enhance therapies for inflammatory bowel disease through artificial intelligence. This collaboration is part of a wider industry movement towards utilizing AI in drug discovery and development, particularly for complex diseases like IBD. AI's ability to process large datasets and identify potential therapeutic targets faster and more accurately is revolutionizing how companies approach drug development. In clinical trial news, Praxis Precision Medicines has reported positive phase 3 results for ulixocaltamide in treating essential tremor. This outcome reverses prior concerns from interim analyses and illustrates the persistent innovation in neurological disorder treatments. Similarly, Icuries has announced successful results from its Phase 3 trial of Priglovir for refractory herpes simplex virus infection infections in immunocompromised patients. This success paves the way for an FDA filing demonstrating ongoing progress in antiviral therapy development. Novartis is also making strides with favorable outcomes from its phase three trial of Phabalta for egonephropathy. As a complement factor B inhibitor, Phabalta has shown efficacy in slowing kidney function decline, which may lead to a new standard of care for this chronic kidney disease. Novartis plans to file these findings with regulatory bodies soon, highlighting its strategic focus on diversifying into rare kidney diseases. Turning to industry trends, there is significant investment activity in antibody drug conjugates. French biotech company AD Safarix has raised $122 million to advance these targeted therapies into clinical trials. ADCs are gaining traction due to their precision in targeting cancer cells while minimizing damage to healthy tissues. Such advancements signal a potential shift in cancer treatment paradigms toward more targeted and less toxic therapies. Similarly, Tubulus raised an impressive Series C funding round to advance work on ADCs targeting ovarian and lung cancers, underscoring the growing interest in the potential of ADCs engineered to deliver cytotoxic drugs specifically to cancer cells. In another intriguing development, research has shown that a common diabetes drug can alleviate brain inflammation in female mice with multiple sclerosis. This finding exemplifies the growing interest in drug repurposing as a strategy to accelerate development timelines and reduce costs by leveraging existing SAFET profiles. On the regulatory front, the federal government shutdown has highlighted vulnerabilities in healthcare funding and policy stability in the US Potentially impacting drug approval timelines and healthcare access. Additionally, the formation of new alliances like the Governor's Public Health alliance signifies a shift towards regional healthcare governance amid growing distrust in federal health bodies. In other significant updates, Johnson and Johnson is seeking regulatory approval for a combination therapy using Techvile and DarzaLex FastPro as a second line treatment for newly diagnosed diagnosed multiple myeloma patients. Positive phase three trial results suggest this combination could shift treatment paradigms for this rare blood cancer by offering an effective alternative at earlier stages. Merckx Keytruda continues to expand its reach within oncology following positive outcomes from a pivotal ovarian Cancer Study. Keytruda demonstrated improved overall survival regardless of PD L1 expression levels, reinforcing its role as a cornerstone of cancer immunotherapy. On the innovation front, Varidermyx has secured $150 million in Series C funding to advance an extended release oral minoxidil formulation for pattern hair loss. This initiative aims to fill a significant market gap by providing a more effective delivery system for hair growth treatment. The hair growth sector is experiencing a surge in investment activity highlighted by Varadermics successful Series C funding round and Pelage Pharmaceuticals Raise, indicating robust investor interest in novel therapies for conditions like androgenetic alopecia. Additionally, regulatory updates include China's approval of GlaxoSmithKline's Shingrix vaccine for at risk adults, a step that underscores global expansion efforts within preventive healthcare measures. Novo Nordisk headlines aggressive expansion into rare disease therapeutics, evidenced by an offer of up to $2 billion for Amaero's complement drug, signaling a commitment to bolstering its rare disease pipeline following a strategic pivot away from cell therapy initiatives. This realignment reflects a broader industry trend where companies increasingly focus on niche areas with high growth potential. From a regulatory perspective, the FDA is undergoing significant changes, notably with the reassignment of Sandra Retsky as Orphan Drug Director amid the rollout of Inflation Reduction act exemptions. This development hints at potential shifts in the agency's focus and strategy, particularly in the orphan drug sector. The pharmaceutical and biotech sectors are experiencing significant advancements in strategic movements highlighted by recent funding rounds, licensing deals and clinical trial results. Boehringer, Ingelheim and Aimed Bio have entered into a licensing agreement to co develop ADCs, further cementing the strategic importance of ADCs in oncology. Similarly, Novo Nordisk partnered with Amaos on Zoltemibert for rare diseases, demonstrating the industry's continued commitment to addressing unmet medical needs. Collaborative efforts in metabolic diseases are also noteworthy. Eli Lilly's GLP1 agonist orforglipron achieved phase three endpoints for type 2 diabetes, setting the stage for regulatory filing. GLP1 agonists have become a cornerstone of diabetes management due to their efficacy in controlling blood glucose levels and potential weight loss benefits. Overall developments underscore a dynamic period in the pharmaceutical and biotech industries characterized by a blend of scientific innovation, strategic partnerships and significant financial investments. Ongoing advancements in targeted therapies, regenerative medicine and AI driven drug discovery are poised to significantly impact patient care and drug development, paving the way for personalized and effective treatment options across various therapeutic areas. As we continue our exploration into technological integration within pharmaceutical biotech industries, Charles River Laboratories appointed a former FDA leader as chair of an Advisory board on animal testing alternatives. This move reflects growing momentum towards developing new approach methodologies aimed at reducing or replacing animal testing. Almic Group's substantial investment in the new Almic Trial Coordinator platform marks a significant leap in e clinical offerings. This interoperable clinical trial technology aims to streamline trial management and enhance data integration in corporate legal. The ongoing Novo Nordisk vs. KBP case highlights complexities due diligence high stakes acquisitions acquisition biotech anomalous phase results raises questions adequacy due diligence process particularly given another potential buyer identified significant data imbalances case underscores critical importance thorough due diligence pharmaceutical mergers acquisitions mitigate financial strategic risks AI continues transformative force drug disclosure discovery evidence Takeda partnership AI designer Nabla Bio collaboration reflects Takeda's pivot away cell therapies focus AI driven modalities emphasizing growing confidence AI's potential enhanced discovery efficiency innovation similarly shuttle pharmaceuticals acquisition molecule AI marks entry AI discovery space highlighting sector's increasing reliance AI accelerate refined development Novo Nordisk Indiana plant received official action indicated label FDA agency's most severe inspection classification Development signals potential delays partners underscores critical importance regul compliance maintaining operational continuity market access FDA stringent oversight serves reminder regulatory challenges companies face Ensuring manufacturing excellence adherence quality standards BioNTech Initiative Establish MRNA Vaccine Production Africa supported EU funding represents strategic effort bolstered global equity Pandemic preparedness move addresses regional health disparities underscores importance decentralized production capabilities enhancing global resilience Overall developments highlight dynamic nature Pharmaceutical biotech industries characterized technological innovation strategies strategic realignments regulatory challenges integration AI discovery efforts advance NAM's ongoing emphasis compliance poised shape Future landscape developments trends hold significant implications Care offering promise efficient ethical innovative therapeutic solutions thanks Tuning Pharma Daily Be sure. Join us next time. Stay informed. Latest industry updates have Great day ahead Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of major advancements and strategic moves that are shaping the future of healthcare. A significant development comes from AstraZeneca, which has committed a substantial $445 million investment to bolster production at its Texas facility for La Kelma, a treatment designed for hyperkalemia. Hyperkalemia is a condition characterized by elevated potassium levels in the blood, posing serious health risks if not managed properly. This investment highlights AstraZeneca's dedication to meeting growing global demand and enhancing patient access to this vital treatment. By strengthening its production capabilities, the company aims to ensure a more reliable supply chain, potentially leading to better outcomes for patients worldwide. Meanwhile, Pfizer is making noteworthy progress in the realm of oncology. Recent clinical trial results have positioned tuisa, developed in collaboration with Segin, as a promising candidate for first line maintenance therapy in HER2 positive breast cancer. The potential shift from second line to first line treatment could significantly alter patient care by offering an effective therapeutic option earlier in the disease management process. This advancement underscores Pfizer's commitment to improving long term outcomes for patients battling this aggressive form of cancer. In legal news, a dispute between Novo Nordisk and KBP Pharmaceuticals has underscored the critical importance of transparency and thorough due diligence in biotech transactions. The controversy Involves anomalous Phase 2 clinical trial results that Novo Nordisk claims were not adequately disclosed by kbp. Such cases highlight the necessity for rigorous investigation during mergers and acquisitions to prevent costly legal battles and ensure informed decision making in drug development partnerships. On the HIV prevention front, GSK has released promising data for its long acting pre exposure prophylaxis drug. This new data suggests Apretude holds higher acceptability compared to Gilead's competing product YITS2GO. Improved patient adherence could shift market dynamics towards GSK's favor, potentially enhancing public health outcomes by preventing HIV infections more effectively. Manufacturing innovations are also taking center stage as Particle Dynamics collaborates with a former Euro API plant to introduce cotis, a new contract development and manufacturing organization. COTIS will offer comprehensive services such as spray drying and particle engineering, aligning with growing demand for specialized pharmaceutical manufacturing capabilities. Turning our attention to diabetes treatment advancements, Eli Lilly's oral GLP1 candidate orforglipron has demonstrated superiority over both placebo and AstraZeneca's Farxiga in phase 3 trials for type 2 diabetes. This success strengthens Eli Lilly's portfolio in a highly competitive market and could lead to regulatory approval next year. An oral treatment option could significantly enhance patient compliance compared to existing injectable GLP1 therapies in oncology. Boringer Ingelheim has entered into a deal worth up to $991 million with aimed bio, focusing on antibody drug conjugates that target proteins involved in tumor growth and resistance. This collaboration highlights the increasing interest in ADCs as targeted cancer therapies capable of minimizing systemic toxicity while delivering potent cytotoxic agents directly to cancer cells. The industry continues to be shaped by funding rounds and strategic acquisitions. Novo Nordisk's acquisition of Amaero's MASP3 inhibitor zoltanibert for $2.1 billion marks a significant move in rare disease therapeutics. Despite Emero's pausing development, Novo Nordisk sees potential in treating paroxysmal nocturnal hemoglobinuria, reinforcing its commitment to expanding its rare disease portfolio. Meanwhile, technological integration is gaining momentum. Companies like Lila sciences are leveraging artificial intelligence to accelerate drug discovery processes. Their expanded Series A funding aims to utilize scientific superintelligence for faster development timelines, reflecting the increasing role of AI technologies in biotech research. Rounding out today's coverage are strategic collaborations aimed at revolutionizing drug development processes. Bristol Myers Squibb has deepened its partnership with Insitro by committing over $2 billion towards neurodegenerative disease research, specifically focusing on amyotrophic lateral sclerosis. Such alliances underscore the importance of pooling resources and expertise to tackle complex diseases requiring innovative scientific approaches. Collectively, these developments illustrate ongoing innovation in strategic maneuvering within the pharmaceutical and biotech industries. Companies are increasingly focusing on advanced manufacturing technologies, precision medicine approaches like ADCs and GLP1 therapies, and strategic collaborations to enhance their competitive edge. The emphasis on rigorous clinical trial evaluation and transparent data sharing remains critical as these industries navigate regulatory landscapes and strive for successful therapeutic advancements. As we witness these transformative changes unfold, it's clear that the pharmaceutical and biotech sectors are dedicated to improving patient care through innovative solutions that drive progress forward. Thank you for tuning in to Pharma Daily your go to source for all things pharma and biotech. Stay tuned as we continue to bring you the latest insights from this ever evolving industry. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we explore the rapidly evolving landscape of the pharmaceutical and biotech sectors where regulatory updates, strategic mergers and scientific breakthroughs are continually reshaping the industry, starting with Novo Nordisk's recent challenges. Their newly acquired manufacturing facility in Indiana has been flagged by the FDA with an official Action Indicated designation. This classification being the most severe level of inspection categorization, potentially signals delays in production and collaboration with partners like Regeneron and Scholarruck. Such regulatory hurdles underscore the vital importance of compliance in ensuring smooth supply chains and market availability of therapeutics. It's a stark reminder of how critical regulatory oversight is in maintaining quality assurance within pharmaceutical manufacturing. Meanwhile, Johnson and Johnson is navigating its own regulatory landscape by engaging with the Trump administration on drug pricing reforms. These discussions highlight the broader industry's ongoing efforts to adapt to evolving regulatory frameworks and market dynamics. By spinning off its orthopedics unit, JJ aims to sharpen its focus and drive growth in more strategic areas, illustrating a trend towards specialization as companies strive to align with market demands in mergers and acquisitions News Biocryst Pharmaceuticals has completed a significant $700 million acquisition of Astrea Therapeutics. This move positions Biocryst to compete directly with Takeda's hereditary angioedema therapy. The acquisition emphasizes the competitive nature of specialty markets and highlights how targeted acquisitions can expand therapeutic pipelines. Halozyme Therapeutics is similarly active in pursuing mergers and acquisitions to enhance its drug delivery capabilities. Their recent acquisition of Electro Fee aligns with Halozyme's strategy to innovate in drug delivery technologies, which are increasingly recognized for their role in improving therapeutic efficacy and patient experience. Funding models are also evolving within the industry as alternative programs for specialty drugs gain attention for their potential cost saving benefits for self insured employers. However, these models raise ethical concerns due to potential financial risks shifting onto patients. This ongoing debate underscores the complexity of balancing cost management with patient access in healthcare. Biontech's initiative to establish MRNA vaccine production facilities in Africa represents a significant step towards enhancing vaccine accessibility and equity on a global scale. Supported by European Union funding, this move underscores the importance of regional manufacturing hubs in facilitating rapid distribution of life saving vaccines. Turning our focus to clinical advancements, Roche and Eli Lilly's collaboration has led to FDA approval of an Alzheimer's blood test for primary care use. This diagnostic tool could significantly enhance the adoption of Alzheimer's treatments like Biogen's Lekembi by streamlining diagnosis processes in primary care settings. Novo Nordisk's Indiana facility has again made headlines due to FDA scrutiny, potentially impacting partnerships with major players such as Regeneron. This situation highlights how stringent compliance requirements can influence strategic partnerships and operational timelines. On a promising note, Caylara Therapeutics has raised $600 million in funding to advance its obesity treatment program into Phase three trials, with Bain Capital leading this round. It reflects investor confidence in targeting metabolic disorders, a growing area of focus given their widespread health implications. Artificial intelligence continues to reshape drug discovery processes. Takeda Pharmaceuticals, $1 billion partnership with AI drug designer Nabla Bio exemplifies this trend, illustrating how AI integration can enhance innovation and efficiency in developing novel therapeutics. In cardiovascular therapeutics, Cardigan's successful $254 million Series B funding round supports its late stage clinical pipeline advancements, reflecting a broader industry emphasis on addressing high burden diseases through innovative solutions. Denali Therapeutics faces regulatory challenges as delays occur in FDA decision making regarding its Hunter syndrome drug. This setback is a reminder of the complexities biotech firms navigate within approval processes for rare disease treatments. Furthermore, California Governor Gavin Newsom's legislation targeting pharmacy benefit managers aims to increase transparency and accountability within this influential sector of drug pricing and access as we delve into strategic corporate maneuvers. Novo Nordisk's decision to close its cell therapy unit signifies a shift towards reprioritizing resources away from cell based diabetes treatments. This reflects a broader industry trend towards exploring potentially more lucrative or promising therapeutic avenues. Cavaletta Bio's advancement in CAR T therapy showcases innovation within autoimmune disorder treatments by eliminating pathogenic B cells without preconditioning chemotherapy, potentially reducing treatment toxicity significantly. AI driven drug discovery gains momentum with Sanofi's collaboration with BenchSci and Shuttle Pharmaceuticals acquisition of Molecule AI. These initiatives highlight AI's growing role in enhancing preclinical research efficiency and accuracy within drug development pipelines. AstraZeneca's commitment to transparency through its new discovery center underscores an industry wide push for openness within research processes key to fostering trust and accelerating scientific advancement through collaborations in oncology. Dual genetic testing for multiple myeloma patients at the Institute of Cancer Research emerges as a more precise method for identifying those at risk of early relapse compared to traditional approaches. This development exemplifies how combining DNA and RNA analyses can refine diagnostic precision and tailor treatment strategies effectively. Accelargy aims to redefine allergy therapeutics with its $70 million emergence fund aimed at developing a new class of drugs that revolutionize standard care practices for allergic diseases, a testament to dynamic biotech research addressing unmet medical needs through novel modalities. Despite these advancements, external factors such as government shutdowns pose risks by disrupting healthcare operations and research funding flows. Recent political gridlocks remind us of vulnerabilities within health services impacting regulatory processes and industry operations alike. Overall, these developments illustrate an industry poised on significant transformation driven by technological advancements and strategic recalibration. The emphasis on AI integration, precision medicine through genetic testing and innovative therapeutic approaches signals robust progress towards personalized healthcare solutions that promise substantial impacts on patient care globally. As these trends unfold further, they offer exciting prospects for redefining modern medicine's landscape profoundly. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Lets dive into the latest news shaping this dynamic industry. Bristol Myers Squibb recently made headlines with their acquisition of Orbital Therapeutics for a remarkable $1.5 billion. This strategic move is aimed at enhancing their in vivo cell therapy capabilities, particularly in treating autoimmune disorders. In vivo cell therapy is a pioneering approach that allows genetic modifications directly within a patient's body, potentially revolutionizing the treatment landscape for numerous conditions. This acquisition underscores Bristol Myers Squibb's commitment to pushing the boundaries of innovative cell therapy technologies and reflects a broader trend in the industry towards personalized medicine. In another significant development, AstraZeneca has aligned with the Trump administration's Most Favored Nation pricing program, agreeing to provide Medicaid drugs at prices competitive on a global scale. This decision marks a strategic shift towards cost reduction, especially in chronic disease management and respiratory therapeutics. The move is indicative of AstraZeneca's efforts to adapt to regulatory pressures and evolving policies that emphasize value based healthcare delivery. Meanwhile, IPSOMED has announced plans to invest $248 million in establishing a manufacturing facility in North Carolina. This facility will focus on producing auto injectors essential for treating diabetes and metabolic disorders. The investment signifies a strategic operational expansion aimed at meeting rising demand in North America, highlighting the growing importance of drug delivery devices in the therapeutic landscape. Turning to clinical trials, Regeneron has unveiled promising phase 1 half data for its DBoto gene therapy targeting genetic hearing loss in children. By using AAV vectors to address DFNB9 related synaptic transmission deficits, this therapy could mark a breakthrough for those suffering from hereditary hearing conditions. Satelose has also presented encouraging phase 1 results for SAT3247, an oral small molecule targeting AAK1 in Duchenne muscular dystrophy, with plans to proceed to phase 2 trials focused on muscle regeneration in oncology. Taejo and Cullinan's phase 2 data on zip alertinib showed efficacy against EGFR mutated non small cell lung cancer with brain metastasis. This advancement highlights the potential of tyrosine kinase inhibitors in precision oncology. Similarly, Arcis Biosciences reported a median survival of 26.7 months for its combination therapy with Domvanilimab and Zimbrilimab gastroesophageal adenocarcinoma trials, underscoring the promise of TIGIT targeted therapies assembly. Biosciences has shared promising phase 1b results for its ABI5366 helicase primase inhibitor, achieving an impressive 94% reduction in herpes simplex virus shedding os. Therapies reported significant survival improvement with its OSTHR2 vaccine in recurrent pulmonary metastatic osteosarcoma patients, positioning HER2 targeting immunotherapies as promising cancer treatment interventions. Cavaletta Bio has made strides with its rhes Cabtagene autolucyl CAR T therapy demonstrating B cell elimination without preconditioning in Pemphigus vulgaris trials. This innovation opens new doors for autoimmune disease management through advanced cell therapies. On the business development front rocksout licensing of its GLP1 GIP Agonist Court 388 to Chu Guy for diabetes and obesity treatment exemplifies strategic partnerships focused on addressing MET disorders through novel small molecules. The sector is also witnessing significant financial activities, with Evomune filing an IPO to advance treatments for inflammatory conditions. Meanwhile, coin Pharmaceuticals raised $104.5 million through private placement to concentrate on rare diseases. Johnson and Johnson has emerged as a key player on the mergers and acquisitions front, reportedly engaging in talks to acquire Protagonist therapeutics for over $4 billion. This move reflects ongoing interest in peptide based autoimmune therapies and signals continued consolidation within the industry. These developments collectively highlight a dynamic pharmaceutical landscape characterized by strategic acquisitions, regulatory adaptations and innovative clinical advancements poised to reshape patient care across various medical domains. In related news, AstraZeneca's CEO recently visited the White House to formalize an agreement regarding drug pricing with then President Donald Trump. This action underscores the ongoing pressure on pharmaceutical companies to align with governmental pricing strategies, a significant factor influencing drug affordability and market dynamics. Regulatory updates continue to play a crucial role in shaping industry practices. The FDA recently added a warning label to Johnson and Johnson and Legend Biotech's Carviq T, a multiple myeloma treatment, highlighting a potentially fatal risk of an intestinal inflammatory disorder associated with the drug. This highlights the importance of post market surveillance and vigilance regarding adverse effects. As part of patient safety efforts, Teva Pharmaceuticals received FDA clearance for an expanded label on uzedy, its long acting bipolar disorder treatment. This approval underscores ongoing efforts to enhance therapeutic options for mental health conditions by offering more effective management tools through extended release formulations. Novo Nordisk's decision to shutter its cell therapy unit marks a significant pivot away from efforts focused on curing type 1 diabetes. The restructuring, which affects nearly 250 employees, illustrates challenges biotech companies face when balancing innovative research pursuits with economic viability considerations. Mergers and acquisitions continue reshaping the industry landscape, as evidenced by Johnson and Johnson's potential acquisition of Protagonist Therapeutics, a move poised to Strengthen J&J's immunology portfolio and reflect large pharmaceutical firms efforts to bolster capabilities through strategic partnerships and acquisitions. On a broader scale, healthcare operations are feeling impacts from federal government shutdowns that began October 1st. Reductions at HHS and CDC illustrate how such administrative challenges can affect public health initiatives and regulatory activities, underscoring governmental stability's interconnectedness with healthcare delivery. Scientific advancements continue driving progress across patient care domains, notably from Institute cancer research findings suggesting combined DNA RNA testing offers superior accuracy in identifying blood cancer patients at early relapse risk versus traditional methods demonstrating precision medicine growing role optimizing treatment strategies while improving outcomes. Technological innovations are also making waves. Nine Louisiana health systems have implemented Epic's MyChart Central feature, a unified login hub allowing patients streamlined access representing shifts towards integrated digital health solutions aimed at enhancing engagement alongside streamlining healthcare access processes. Overall, these elements collectively influence drug development dynamics alongside market trends shaping today's evolving pharmaceutical landscape. Demonstrating stakeholders must navigate complex regulatory frameworks while fostering innovation, effectively meeting emerging healthcare needs globally moving forward into future years ahead as our coverage continues unfolding key developments impacting these sectors further along this journey together exploring how scientific breakthroughs, regulatory adaptations, business transformations all contribute reshaping tomorrow's global healthcare landscape. Future possibilities lie ahead patiently waiting discovery exploration each step journey unveiling new opportunities unlock full potential. Stay tuned here Pharma Daily your trusted source Reliable, insightful updates every step way that concludes our Week in review for October 17, 2025 covering four episodes from October 14 to October 17. Thank you for listening to Pharma Daily's Week in Review. Join us tomorrow for more breaking news and analysis from the pharmaceutical and biotech world.